ijms-logo

Journal Browser

Journal Browser

The Latest Molecular Research on Renal Disease

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 30 August 2025 | Viewed by 688

Special Issue Editors


E-Mail Website
Guest Editor
1. Department of Biomedicine, Aarhus University, 8000 Aarhus, Denmark
2. Department of Renal Medicine, Aarhus University Hospital, 8200 Aarhus N, Denmark
Interests: organ transplantation; renal disease; kidney disease

E-Mail Website
Guest Editor
Department of Clinical Medicine, Aarhus University, 8200 Aarhus, Denmark
Interests: stem cells; kidney transplantation; ex vivo perfusion

Special Issue Information

Dear Colleagues,

Renal disease encompasses a broad range of conditions such as glomerulonephritis, ischemic nephropathy, and diabetic nephropathy and remains a significant health issue. While the clinical management of kidney diseases has advanced over the last few years, molecular research continues to provide insights into pathogenesis, diagnosis, and potential therapies.

This Special Issue will cover all aspects of molecular research related to acute and chronic kidney injury, including both animal models and clinical studies in patients.

We invite the submission of scientific papers, including reviews as well as original investigations, within this research field. Potential topics include molecular mechanisms, novel genetic insights, stem cell and regeneration therapy, microRNAs, epigenetics, and novel therapeutic targets.

1. Molecular Mechanisms behind Kidney Injury

Recent molecular research has significantly enhanced our understanding of the cellular and molecular pathways involved in kidney injury. A key focus has been the role of inflammation, fibrosis, and oxidative stress.

  • Inflammation: The inflammatory response is central to the development and progression of renal diseases. The activation of immune cells, such as T-cells and macrophages, contributes to tubulointerstitial fibrosis. A variety of cytokines and growth factors (e.g., TNF-alpha, IL-6) are upregulated, leading to further injury to renal structures.
  • Fibrosis: Renal fibrosis is considered the final common pathway in many forms of kidney disease, leading to irreversible damage and the loss of kidney function. The role of myofibroblasts in the progression of fibrosis has been widely studied, with research focusing on signaling pathways such as TGF-β and Wnt/β-catenin that regulate fibrotic processes.
  • Oxidative Stress: Oxidative stress, resulting from an imbalance between reactive oxygen species (ROS) and antioxidant defenses, is a central factor in kidney injury. Studies have elucidated the molecular pathways by which oxidative stress induces renal cell damage and promotes inflammation and fibrosis.

2. Genetic Insights into Renal Disease

A growing body of research has identified genetic variants linked to various kidney diseases. Genome-wide association studies (GWASs) have uncovered several genetic loci associated with CKD, offering insights into the molecular underpinnings of these diseases. These include variants in genes such as APOL1, UMOD, and NOS3, which have been associated with an increased risk of kidney disease.

  • APOL1 Gene: The APOL1 gene has garnered significant attention due to its association with increased susceptibility to kidney diseases in individuals of African descent. Variants of APOL1 have been shown to confer risk for conditions like focal segmental glomerulosclerosis (FSGS) and HIV-associated nephropathy.
  • UMOD Gene: Mutations in the UMOD gene, which encodes uromodulin, a protein expressed in the kidneys, are linked to medullary cystic kidney disease and CKD. Uromodulin has a protective role in the kidneys, and alterations in its expression can contribute to disease progression.
  • NOS3 Gene: Variants in the NOS3 gene, which encodes endothelial nitric oxide synthase, have been implicated in hypertension-related kidney damage. Nitric oxide is important in regulating vascular tone and kidney perfusion, and its dysfunction may contribute to renal injury.

3. Renal Regeneration and Stem Cell Research

One exciting area of research in renal disease is the potential for renal regeneration through stem cell therapy. Recent advancements in the identification of renal progenitor cells and induced pluripotent stem cells (iPSCs) have opened up new avenues for therapeutic interventions.

  • Renal Progenitor Cells: Studies have identified specific populations of cells within the kidney that have the potential to regenerate damaged renal tissue. Research is focusing on how these progenitor cells can be activated or transplanted to repair renal damage.
  • iPSCs: Induced pluripotent stem cells (iPSCs) have been used to model renal diseases in vitro, enabling the study of disease mechanisms and drug testing. These cells can be differentiated into various renal cell types, offering a potential strategy for kidney repair and regeneration.

4. The Role of MicroRNAs and Epigenetics

MicroRNAs (miRNAs), small non-coding RNAs that regulate gene expression, are emerging as important regulators of kidney function and disease. Research has identified miRNAs that modulate key pathways involved in kidney fibrosis, inflammation, and apoptosis.

  • miRNAs in Fibrosis: Several miRNAs, including miR-21 and miR-29, have been shown to be involved in the regulation of fibrosis by targeting genes that control extracellular matrix deposition and myofibroblast differentiation.
  • Epigenetic Modifications: Epigenetic changes, such as DNA methylation and histone modifications, have been shown to play a role in the pathogenesis of kidney disease. These modifications can alter the expression of genes involved in renal injury and repair, and understanding these changes could lead to novel therapeutic approaches.

5. Emerging Therapeutic Targets

Molecular research on kidney diseases has paved the way for the development of novel therapeutic strategies aimed at specific molecular pathways.

  • Anti-Fibrotic Agents: Targeting fibrotic pathways holds great promise for preventing or reversing kidney damage. Agents that inhibit TGF-β signaling or block the Wnt/β-catenin pathway are being explored in clinical trials.
  • Gene Therapy: With the identification of specific genetic mutations responsible for kidney disease, gene therapy offers a potential route for addressing the root cause of genetic renal diseases. This could involve correcting defective genes or delivering therapeutic genes to the kidneys.
  • Targeting Inflammation: Drugs that target inflammatory pathways, such as inhibitors of TNF-alpha, IL-6, or complement pathways, are being studied for their ability to reduce kidney injury and improve outcomes.

Dr. Niels Henrik Buus
Dr. Marco Eijken
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • renal disease
  • chronic kidney disease
  • renal regeneration
  • kidney injury

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 1517 KiB  
Article
Renal and Vascular Effects of the Allosteric Transglutaminase 2 Modulator LDN-27219 in One-Kidney DOCA–Salt Mice
by Ian Mees, Judit Prat-Duran, Simon Comerma-Steffensen, Ulf Simonsen, Estéfano Pinilla and Niels Henrik Buus
Int. J. Mol. Sci. 2025, 26(12), 5724; https://doi.org/10.3390/ijms26125724 - 14 Jun 2025
Viewed by 546
Abstract
The enzyme transglutaminase 2 (TG2) has an open conformation with transamidase activity which crosslinks matrix proteins contributing to fibrosis development. LDN-27219 promotes the closed conformation of TG2, which can enhance vasodilation, but its effects in renal tissue are unknown. We investigated whether LDN-27219 [...] Read more.
The enzyme transglutaminase 2 (TG2) has an open conformation with transamidase activity which crosslinks matrix proteins contributing to fibrosis development. LDN-27219 promotes the closed conformation of TG2, which can enhance vasodilation, but its effects in renal tissue are unknown. We investigated whether LDN-27219 treatment affects albuminuria and markers of renal fibrosis as well as ex vivo vasodilatation. Male C57BL/6 mice (n = 48) underwent unilateral nephrectomy plus insertion of a deoxycorticosterone acetate pellet (DOCA group) or nephrectomy only (sham group). Both groups were randomized to intraperitoneal treatment with either LDN-27219 (8 mg/kg twice daily) or vehicle for 2 weeks. Urine albumin excretion was evaluated by metabolic cages. Kidney tissue fibrosis markers were assessed by qPCR and Western blotting, while the TG2 conformational state was evaluated using native gel electrophoresis. Collagen staining was performed using Picrosirius red and quantified under circularly polarized light. Mesenteric arteries were mounted in wire myographs for evaluation of vasorelaxation. DOCA mouse developed significant albuminuria (p < 0.001 vs. sham), but neither TG2 mRNA nor protein expression was upregulated in the kidney. However, the relative amount of TG2 in the closed conformation was higher in DOCA mice. LDN-27219 did not affect albuminuria, but LDN-27219-treated DOCA mice showed less urine production and less collagen staining than vehicle-treated DOCA mice. LDN-27219 did not affect TG2 mRNA or TG2 protein expression or mRNA of fibrosis markers. LDN-27219-treated mice had enhanced vasorelaxation to the nitric oxide donor sodium nitroprusside. In conclusion, LDN-27219 treatment in the one-kidney DOCA–salt model did not affect renal TG2 mRNA and protein expression or albuminuria but still exerted beneficial effects in terms of reduced kidney fibrosis and urine production in addition to enhanced vasodilatation. Full article
(This article belongs to the Special Issue The Latest Molecular Research on Renal Disease)
Show Figures

Figure 1

Back to TopTop